Effect of Empagliflozin Beyond Glycemic Control: Cardiovascular Benefit in Patients with Type 2 Diabetes and Established Cardiovascular Disease

The prevalence of type 2 diabetes (T2D) continues to increase, and its association with cardiovascular (CV) disease has led to the inclusion of CV endpoints in clinical trials on the treatment of T2D. This article explores the various trials already performed and under development in this field, wit...

Full description

Bibliographic Details
Main Author: Monteiro, P (author)
Other Authors: Aguiar, C (author), Matos, P (author), Silva-Nunes, J (author), Birne, R (author), Branco, P (author), Calado, J (author), Melo, M (author), Polónia, J (author)
Format: article
Language:eng
Published: 2021
Subjects:
Benzhydryl Compounds
Blood Glucose
Glucosides
Humans
Sodium-Glucose Transporter 2 Inhibitors
Cardiovascular Diseases
Diabetes Mellitus, Type 2
HCC END
HCC NEF
Online Access:http://hdl.handle.net/10400.17/3563
Country:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/3563

Internet

http://hdl.handle.net/10400.17/3563

Similar Items